Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03165188 · ClinicalTrials.gov registry record
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
A clinical trial, sponsored by NewLink Genetics Corporation.
- Terminated
- Registry status
- 29
- Enrollment target
NCT03165188 is a clinical trial that was terminated before completion, run by NewLink Genetics Corporation. The registered enrollment target is 29 participants.
The verdict
NCT03165188 was terminated before completion, sponsored by NewLink Genetics Corporation.
- TERMINATED
- Registry status
- 29 participants
- Enrollment target
Study Summary
This protocol (NLG0705) provides a mechanism for the 15-year follow-up period that the FDA requires for all participants in gene transfer protocols and assures that adequate follow-up can be maintained for subjects who have received at least one dose of algenpantucel-L.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2020-12-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03165188
The ClinicalTrials.gov registry entry for NCT03165188 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewLink Genetics Corporation, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03165188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03165188 about?
NCT03165188 is a clinical study titled "Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy". This protocol (NLG0705) provides a mechanism for the 15-year follow-up period that the FDA requires for all participants in gene transfer protocols and assures that adequate follow-up can be maintained for subjects who have received at least one dose of algenpantucel-L.
What is the current status of trial NCT03165188?
This trial is currently terminated. The enrollment target is 29 participants. The study started on 2017-09-01. Estimated completion is 2020-12-08.
Who is sponsoring clinical trial NCT03165188?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.